Vanguard Group Inc. Cuts Stock Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Vanguard Group Inc. trimmed its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 22.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,013,558 shares of the company's stock after selling 592,205 shares during the period. Vanguard Group Inc. owned approximately 3.50% of Ginkgo Bioworks worth $19,773,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of DNA. FNY Investment Advisers LLC grew its holdings in Ginkgo Bioworks by 125.6% during the 4th quarter. FNY Investment Advisers LLC now owns 75,966 shares of the company's stock valued at $745,000 after buying an additional 42,298 shares in the last quarter. SG Americas Securities LLC purchased a new position in Ginkgo Bioworks during the fourth quarter valued at approximately $199,000. KBC Group NV bought a new stake in Ginkgo Bioworks during the 4th quarter worth approximately $31,000. Forbes J M & Co. LLP lifted its stake in Ginkgo Bioworks by 461.4% in the 4th quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock worth $6,891,000 after purchasing an additional 576,732 shares in the last quarter. Finally, Palumbo Wealth Management LLC bought a new position in Ginkgo Bioworks in the 4th quarter valued at $144,000. Institutional investors own 78.63% of the company's stock.

Ginkgo Bioworks Stock Up 2.5 %

NYSE:DNA traded up $0.19 during trading hours on Tuesday, hitting $7.53. 952,143 shares of the company's stock traded hands, compared to its average volume of 1,497,018. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.00 and a 52 week high of $45.20. The business's fifty day simple moving average is $8.14 and its two-hundred day simple moving average is $9.16. The firm has a market cap of $436.71 million, a P/E ratio of -0.58 and a beta of 1.34.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.